ValiRx (LSE:VAL) Other Stockholders Equity : £2.30 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Other Stockholders Equity?

ValiRx's Other Stockholders Equity for the quarter that ended in Jun. 2023 was £2.30 Mil.

ValiRx's quarterly Other Stockholders Equity increased from Jun. 2022 (£1.96 Mil) to Dec. 2022 (£11.83 Mil) but then declined from Dec. 2022 (£11.83 Mil) to Jun. 2023 (£2.30 Mil).

ValiRx's annual Other Stockholders Equity declined from Dec. 2020 (£11.39 Mil) to Dec. 2021 (£11.34 Mil) but then increased from Dec. 2021 (£11.34 Mil) to Dec. 2022 (£11.83 Mil).

ValiRx Other Stockholders Equity Historical Data

The historical data trend for ValiRx's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Other Stockholders Equity Chart

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Stockholders Equity

Get a 7-Day Free Trial

10.21

2.07

11.39

11.34

11.83

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Other Stockholders Equity	Get a 7-Day Free Trial															1.72	11.34	1.96	11.83	2.30

ValiRx Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

ValiRx Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of ValiRx's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.